Antifibrinolytic agents reduce tissue plasminogen activator-mediated neuronal toxicity in vitro

Acta Anaesthesiologica Scandinavica

Volumn 53, Issue 3, 2009, Pages 325-331

  Sun, H Y ^a   Szlam, F ^a   Levy, J H ^a   Csete, M E ^a   Tanaka, K A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BROMINE DERIVATIVE; HIRULOG; PLASMINOGEN ACTIVATOR INHIBITOR; PROPIDIUM IODIDE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ARTICLE; BRAIN PROTECTION; CELL ASSAY; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; NERVE CELL CULTURE; NEUROBLAST; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CELL LINE; CYTOPROTECTION; FLOW CYTOMETRY; NEURONS; RATS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 60349132116     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01858.x     Document Type: Article

References (32)

1. Yepes M, Lawrence DA. Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004 91 : 457 64.
2. Hastings GA, Coleman TA, Haudenschild CC, Stefansson S, Smith EP, Barthlow R, Cherry S, Sandkvist M, Lawrence DA. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997 272 : 33062 7.
3. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995 377 : 340 4.
4. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001 7 : 59 64.
5. Chandler WL, Fitch JC, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess D. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995 74 : 1293 7.
6. Osterlund B, Andersson B, Haggmark S, Jern C, Johansson G, Seeman-Lodding H, Biber B. Myocardial ischemia induces coronary t-PA release in the pig. Acta Anaesthesiol Scand 2002 46 : 271 8.
7. Aspelin T, Eriksen M, Lindgaard AK, Lyberg T, Ilebekk A. Cardiac fibrinolytic capacity is markedly increased after brief periods of local myocardial ischemia, but declines following successive periods in anesthetized pigs. J Thromb Haemost 2005 3 : 1947 54.
8. Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sci 1992 667 : 249 58.
9. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995 92 : 2236 44.
10. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997 96 : 569 74.
11. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 : 442 8.
12. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research G, Ischemia Research and Education F. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 65.
13. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Investigators of The Multicenter Study of Perioperative Ischemia Research G, Ischemia Research and Education F. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 9.
14. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R, Investigators B. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008 358 : 2319 31.
15. Murtomaki S, Trenkner E, Wright JM, Saksela O, Liesi P. Increased proteolytic activity of the granule neurons may contribute to neuronal death in the weaver mouse cerebellum. Dev Biol 1995 168 : 635 48.
16. Clarkson ED, Edwards-Prasad J, Freed CR, Prasad KN. Immortalized dopamine neurons: a model to study neurotoxicity and neuroprotection. Proc Soc Exp Biol Med 1999 222 : 157 63.
17. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997 91 : 917 25.
18. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004 10 : 1379 83.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method 1983 65 : 55 63.
20. Ormerod MG. Investigating the relationship between the cell cycle and apoptosis using flow cytometry. J Immunol Method 2002 265 : 73 80.
21. Hu CK, Kohnert U, Sturzebecher J, Fischer S, Llinas M. Complexation of the tissue plasminogen activator protease with benzamidine-type inhibitors: interference by the kringle 2 module. Biochemistry 1996 35 : 3270 6.
22. Friedman GC, Seeds NW. Tissue plasminogen activator mRNA expression in granule neurons coincides with their migration in the developing cerebellum. J Comp Neurol 1995 360 : 658 70.
23. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995 270 : 1992 4.
24. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 2001 86 : 138 43.
25. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998 4 : 228 31.
26. Cavaglia M, Seshadri SG, Marchand JE, Ochocki CL, Mee RBB, Bokesch PM. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs. Ann Thorac Surg 2004 78 : 1418 25.
27. Stassen JM, Lambeir AM, Matthyssens G, Ripka WC, Nystrom A, Sixma JJ, Vermylen J. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 1995 74 : 646 54.
28. Mann KG, Williams EB, Krishnaswamy S, Church W, Giles A, Tracy RP. Active site-specific immunoassays. Blood 1990 76 : 755 66.
29. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992 89 : 6040 4.
30. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000 40 : 508 15.
31. Mangano DT. Multicenter Study of Perioperative Ischemia Research G. Aspirin and mortality from coronary bypass surgery. New Engl J Med 2002 347 : 1309 17.
32. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004 104 : 1740 4.